Smith & Nephew's European Trufit Study

NCT ID: NCT01246635

Last Updated: 2021-04-01

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 153 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-15
• Study Completion Date: 2014-12-31

Brief Summary

The purpose of this clinical study is to demonstrate the effectiveness and safety of the Trufit CB (Cartilage Bone) implant for the treatment of single, isolated cartilage defects of the knee compared to Microfracture.

Detailed Description

Up to 315 subjects, ages 18 years and older with a single, isolated cartilage defect of the knee will be randomized in a 1:1:1 ratio to 1 of 3 treatment groups:

• Trufit CB Implant with rehabilitation protocol;
• Trufit CB Implant with rehabilitation protocol;
• Microfracture with rehabilitation protocol

Rehabilitation program may be standard (6 weeks touch weight to full weight bearing) or accelerated (2 weeks touch weight to full weight bearing).

Conditions

Defect of Articular Cartilage

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

TRUFIT CB with accelerated rehab.

Group Type: EXPERIMENTAL

Trufit CB (Cartilage Bone) Implant

Intervention Type: DEVICE

Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.

TRUFIT CB with standard rehab.

Group Type: EXPERIMENTAL

Trufit CB (Cartilage Bone) Implant

Intervention Type: DEVICE

Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.

• Microfracture with rehabilitation

Group Type: ACTIVE_COMPARATOR

Microfracture if the knee

Intervention Type: PROCEDURE

Creation of small holes through subchondral bone with the goal of stimulating cartilage growth

Interventions

Trufit CB (Cartilage Bone) Implant

Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.

Intervention Type: DEVICE

Microfracture if the knee

Creation of small holes through subchondral bone with the goal of stimulating cartilage growth

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Capable of providing informed consent;
• Eighteen (18) years or older and skeletally mature on the date of study enrollment;
• Willing and able to attend all follow up visits and complete all study related procedures and evaluations including, but not limited to adhering to the rehabilitation protocol;
• Single, isolated cartilage defect (ICRS Grade III - IV) in the knee (medial or lateral femoral condyle or trochlea) that is ≥ 1cm2 (10 mm) and ≤ 2cm2 (20 mm) in area and requiring a maximum of 2 implants (if randomized to TRUFIT CB); Note: Lesion size should be assessed as the product of the longest diameter and its perpendicular applied at the widest portion of the lesion.
• Candidate for cartilage repair surgery as a result of a single, isolated symptomatic cartilage lesion;
• Presents with stable health at the time of study enrollment;
• BMI of ≤ 32.

Exclusion Criteria

• Female of child-bearing potential who is pregnant or plans to become pregnant over the course of the study;
• History of alcohol or drug abuse;
• Presents with patellofemoral instability or other anatomical malalignment in the study knee;
• Any diagnosis that would preclude the patient from successfully completing the study rehabilitation protocols;
• Unable or unwilling to follow post operative procedures (e.g. rehabilitation protocol);
• Received one or more intra-articular steroid injections in the study knee within the previous 3 months;
• Presents with ipsilateral hip disease, as determined by pain or restricted range of motion upon physical examination;
• Treated with either an investigational device or drug within one (1) month of study enrollment, or plans to be treated with an investigational device or drug in the next 24 months;
• Diagnosed rheumatoid arthritis, ankylosing spondylitis (Bechterew syndrome), or calcium pyrophosphate dihydrate disease(chondrocalcinosis);
• History of severe vascular or neurological disease, uncontrolled diabetes, or is immunosuppressed (e.g. HIV positive);
• Musculoskeletal disease, including degenerative bone diseases such as osteochondritis dissecans and osteonecrosis;
• Pathologic conditions of the bone (e.g. osteoporosis, cystic changes, hyperparathyroidism, Paget's Disease, hypercalcemia, prolonged use of steroids);
• Active infection, or evidence thereof, at the lesion site;
• Requires the use of any medication(s) or treatment(s) known to have an effect on bone metabolism (e.g. bisphosphonates, chemotherapeutic or immunosuppressive agents);
• Requires concomitant osteotomy, partial lateral meniscectomy or complete meniscectomy; Note: Concomitant ACL reconstruction or revision, as well as meniscal repair and partial medial meniscectomies are permitted under the study protocol.
• Has undergone an ACL reconstruction, osteotomy, chondral resurfacing procedure or partial meniscectomy (≤ central third of the meniscus) in the last year and has not completed at least 6 months of rehabilitation since such surgery; Note: Patients who have undergone these procedures within the last year and have completed at least 6 months of rehabilitation are eligible to participate in the study.
• Any active, implanted medical device (e.g. cochlear implant) or metallic implant (other then dental work) that may interfere with Magnetic Resonance Imaging (MRI);
• Any condition (e.g. claustrophobia) that may interfere with the patient's ability to undergo MRI;
• Diagnosis requiring placement of an active implant (e.g. cardiac pacemaker, vagus nerve stimulator, etc.) within the next 24 months.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Smith & Nephew, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Karl Brabants, MD

Antwerp, , Belgium

Prof. Dr. K.F. Almqvist

Ghent, , Belgium

Toon Claes, MD

Herentals, , Belgium

Johan Vanlauwe

Leuven, , Belgium

Aalborg Private Hospital A/S

Aalborg, , Denmark

Johannes Holz, MD

Hamburg, , Germany

Kevin J. Mulhall

Dublin, , Ireland

Sander Koeter, MD

Nijmegen, , Netherlands

Kees van Egmond, MD

Zwolle, , Netherlands

Lars Engebretsen, MD

Oslo, , Norway

Magnus Forssblad, MD

Stockholm, , Sweden

Angus Robertson, MD

Cardiff, , United Kingdom

Tim Spalding, MD

Coventry, , United Kingdom

David Chesney

Fife Keith, , United Kingdom

Countries

Belgium; Denmark; Germany; Ireland; Netherlands; Norway; Sweden; United Kingdom

Other Identifiers

CSA-2005-02

Identifier Type: -

Identifier Source: org_study_id